The phrase "advanced sample" is correct and usable in written English.
It can be used to describe a sample that is sophisticated, complex, or of a higher level than a basic sample, often in contexts like research, testing, or product development.
Example: "The researchers presented an advanced sample of the new material, showcasing its unique properties and potential applications."
Alternatives: "sophisticated sample" or "complex sample".
The new Flexplex assay coamplifies 23 autosomal STR loci, three Y-STR loci, and amelogenin for advanced sample discrimination.
The primary objective is to demonstrate the key technologies requisite for future advanced sample return mission.
University students were also considered to obtain a first idea of how the test functions in this more advanced sample.
High-resolution structure determination is now routinely performed using advanced sample preparation techniques and image processing software.
The performance of the proposed AGSF is verified using Monte Carlo simulation whose results are compared with other advanced sample based nonlinear filters.
However; we should keep in mind that for several biopsy techniques more advanced sample diagnostic procedures such as cell blocks have to be utilized [5].
We employ advanced sampling techniques involving steered molecular dynamics and metadynamics simulations to obtain the free-energy landscapes of single-strand unfolding and unzipping in a three-stranded assembly.
To accomplish these objectives numerous advanced sampling algorithms have been developed [12], as well as methods to visualize free energy landscapes [13] and determine whether or not they represent the true equilibrium distribution of the system under the given potential [14].
The three candidate miRNAs; miR-34a, miR-150, and miR-923 were analysed in a validation cohort of 97 independent plasma samples comprising 20 normal, 20 polyp, 20 adenoma samples, 23 early stage cancer samples, and 14 advanced cancer samples (see Table 3).> -wrap-foot> Bold text denotes significant comparisons.
Two separate patient cohorts were identified, a discovery set (n = 48) comprising 8 normal, 8 polyp, 16 adenoma samples, 8 early stage cancer samples (stage I/II), and 8 advanced cancer samples (stage III/IV), and a validation set (n = 97) comprising 20 normal, 20 polyp, 20 adenoma samples, 23 early stage cancer samples, and 14 advanced cancer samples.
To facilitate this we performed miRNA profiling for 667 miRNAs on a discovery set of 48 plasma samples comprising 8 normal, 8 polyp, 16 adenoma samples, 8 early stage cancer samples (stage I/II), and 8 advanced cancer samples (stage III/IV).
